An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
The antifibrinolytic activity of cytosol from Dunning R3327H rat prostate tumors was studied. The prostate tumors from rats treated with D-Trp6-LH-RH had 2.5 times lower plasminogen activator activity than tumors from untreated rats. This was due to the presence of an inhibitor of plasminogen activator as well as a reduction in residual activity of plasminogen activator(s). Only the cytosolic extracts from prostate tumors of rats treated with D-Trp6-LH-RH contained this inhibitor. The purified inhibitor (m.w. 21,000), formed a complex with urokinase and partially purified plasminogen activator(s) from prostate tumors of untreated as well as D-Trp6-LH-RH treated rats. The increase in antifibrinolytic activity after treatment with LH-RH analogs may be an important factor in reducing the invasiveness of the prostate tumor.
Hierowski
M T
MT
Schally
A V
AV
D000818:Animals; D003600:Cytosol / Q000032:analysis; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D017329:Triptorelin Pamoate; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors*
D015849:Plasminogen Inactivators; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator